Outcomes in COVID-19 molnupiravir studies
Outcomes in molnupiravir studies.
Potential risks include the creation of dangerous variants and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity Hadj Hassine , Huntsman , Swanstrom , Waters , Zibat . Multiple analyses have identified variants potentially created by molnupiravir
Fountain-Jones , Sanderson , twitter.com . There is substantial publication bias. Multiple trials have not reported results and did not respond to requests
Lawrence .
0
0.5
1
1.5+
All studies
15%
34
109,506
Improvement, Studies, Patients
Relative Risk
Mortality
23%
15
83,307
Ventilation
46%
5
7,016
ICU admission
19%
3
1,836
Hospitalization
2%
18
79,431
Progression
25%
5
33,432
Recovery
19%
9
27,145
Cases
24%
1
1,527
Viral clearance
30%
10
7,150
RCTs
38%
14
32,322
RCT mortality
45%
4
26,955
Peer-reviewed
21%
24
81,355
Prophylaxis
24%
1
1,527
Early
16%
29
84,252
Late
11%
4
23,727
Molnupiravir for COVID-19
c19 early .org Sep 2023
Favors molnupiravir
Favors control
after exclusions
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT)
77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI]
Treatment
Control
Hetero (RCT)
70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Optimus (RCT)
58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Khoo (RCT)
-33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
MOVe-OUT
Jayk Ber.. (DB RCT)
89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT)
46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM)
52%
0.48 [0.40-0.59]
death
1,856 (n)
1,856 (n)
Yip (PSW)
-12%
1.12 [0.68-1.82]
death/ICU
Zou (RCT)
29%
0.71 [0.28-1.85]
recov. time
77 (n)
31 (n)
Flisiak
39%
0.61 [0.38-0.97]
death
20/203
63/387
AGILE CST-2
Khoo (DB RCT)
67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
Kneidinger
-15%
1.15 [0.56-2.37]
severe case
8/46
26/172
Najjar-Deb.. (PSM)
19%
0.81 [0.46-1.43]
death
22/2,661
27/2,661
Arbel 65+
74%
0.26 [0.10-0.73]
death
4/845
137/12,724
Arbel 40-64
-1182%
12.82 [3.41-48.2]
death
4/224
7/6,075
Suzuki (PSM)
-100%
2.00 [0.34-11.9]
death
2/230
3/690
Brown
-101%
2.01 [0.43-9.38]
hosp.
8/442
2/222
PANORAMIC
Butler (RCT)
40%
0.60 [0.14-2.51]
death
3/12,529
5/12,525
Wong (PSM)
24%
0.76 [0.61-0.95]
death
Liu
-162%
2.62 [0.11-60.6]
ICU
1/26
0/16
Sinha (RCT)
65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Zheng
-100%
2.00 [1.23-3.23]
death/hosp.
61/2,689
34/3,331
OT1
Bajema (PSM)
18%
0.82 [0.52-1.29]
death
24/897
29.0/897
Inaba
58%
0.42 [0.02-10.1]
death
0/84
1/210
Zheng (PSW)
-285%
3.85 [1.54-10.0]
death/hosp.
11/802
33/4,836
OT1
Evans
51%
0.49 [0.29-0.83]
death/hosp.
359 (n)
4,973 (n)
Goodwin
-110%
2.10 [0.19-22.9]
death
1/80
2/336
Tazare
-9%
1.09 [0.93-1.27]
death/hosp.
Butt
-9%
1.09 [0.73-1.63]
death/hosp.
48/1,459
44/1,459
Tau2 = 0.25, I2 = 81.9%, p = 0.16
Early treatment
16%
0.84 [0.65-1.07]
287/28,224
582.0/56,028
16% lower risk
033864 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING2
Improvement, RR [CI]
Treatment
Control
035424 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING2
MOVe-IN
Arribas (DB RCT)
-282%
3.82 [0.50-29.1]
death
11/216
1/75
Wan
11%
0.89 [0.81-0.98]
death
704/6,153
2,541/17,283
Tau2 = 0.00, I2 = 0.0%, p = 0.0047
Late treatment
11%
0.89 [0.83-0.97]
715/6,369
2,542/17,358
11% lower risk
MOVe-AHEAD
Alpizar (DB RCT)
24%
0.76 [0.57-1.01]
symp. case
78/763
103/764
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.049
Prophylaxis
24%
0.76 [0.57-1.01]
78/763
103/764
24% lower risk
All studies
15%
0.85 [0.71-1.02]
1,080/35,356
3,227.0/74,150
15% lower risk
34 molnupiravir COVID-19 studies
c19 early .org Sep 2023
Tau2 = 0.14, I2 = 79.4%, p = 0.076
Effect extraction pre-specified
1 OT: comparison with other treatment 2 FUTILITY: terminated for futility, results pending
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT)
77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI]
Treatment
Control
Hetero (RCT)
70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Optimus (RCT)
58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Khoo (RCT)
-33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
MOVe-OUT
Jayk Ber.. (DB RCT)
89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT)
46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM)
52%
0.48 [0.40-0.59]
death
1,856 (n)
1,856 (n)
Yip (PSW)
-12%
1.12 [0.68-1.82]
death/ICU
Zou (RCT)
29%
0.71 [0.28-1.85]
recov. time
77 (n)
31 (n)
Flisiak
39%
0.61 [0.38-0.97]
death
20/203
63/387
AGILE CST-2
Khoo (DB RCT)
67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
Kneidinger
-15%
1.15 [0.56-2.37]
severe case
8/46
26/172
Najjar-Deb.. (PSM)
19%
0.81 [0.46-1.43]
death
22/2,661
27/2,661
Arbel 65+
74%
0.26 [0.10-0.73]
death
4/845
137/12,724
Arbel 40-64
-1182%
12.82 [3.41-48.2]
death
4/224
7/6,075
Suzuki (PSM)
-100%
2.00 [0.34-11.9]
death
2/230
3/690
PANORAMIC
Butler (RCT)
40%
0.60 [0.14-2.51]
death
3/12,529
5/12,525
Wong (PSM)
24%
0.76 [0.61-0.95]
death
Liu
-162%
2.62 [0.11-60.6]
ICU
1/26
0/16
Sinha (RCT)
65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Zheng
-100%
2.00 [1.23-3.23]
death/hosp.
61/2,689
34/3,331
OT1
Bajema (PSM)
18%
0.82 [0.52-1.29]
death
24/897
29.0/897
Inaba
58%
0.42 [0.02-10.1]
death
0/84
1/210
Evans
51%
0.49 [0.29-0.83]
death/hosp.
359 (n)
4,973 (n)
Goodwin
-110%
2.10 [0.19-22.9]
death
1/80
2/336
Tazare
-9%
1.09 [0.93-1.27]
death/hosp.
Butt
-9%
1.09 [0.73-1.63]
death/hosp.
48/1,459
44/1,459
Tau2 = 0.22, I2 = 80.4%, p = 0.032
Early treatment
23%
0.77 [0.60-0.98]
268/26,980
547.0/50,970
23% lower risk
033864 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING2
Improvement, RR [CI]
Treatment
Control
035424 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING2
MOVe-IN
Arribas (DB RCT)
-282%
3.82 [0.50-29.1]
death
11/216
1/75
Wan
11%
0.89 [0.81-0.98]
death
704/6,153
2,541/17,283
Tau2 = 0.00, I2 = 0.0%, p = 0.0047
Late treatment
11%
0.89 [0.83-0.97]
715/6,369
2,542/17,358
11% lower risk
MOVe-AHEAD
Alpizar (DB RCT)
24%
0.76 [0.57-1.01]
symp. case
78/763
103/764
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.049
Prophylaxis
24%
0.76 [0.57-1.01]
78/763
103/764
24% lower risk
All studies
20%
0.80 [0.67-0.95]
1,061/34,112
3,192.0/69,092
20% lower risk
32 molnupiravir COVID-19 studies after exclusions
c19 early .org Sep 2023
Tau2 = 0.12, I2 = 77.9%, p = 0.012
Effect extraction pre-specified
1 OT: comparison with other treatment 2 FUTILITY: terminated for futility, results pending
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT)
77%
0.23 [0.01-5.69]
0/140
1/62
Improvement, RR [CI]
Treatment
Control
MOVe-OUT
Jayk Ber.. (DB RCT)
89%
0.11 [0.01-0.86]
1/709
9/699
Wong (PSM)
52%
0.48 [0.40-0.59]
1,856 (n)
1,856 (n)
Flisiak
39%
0.61 [0.38-0.97]
20/203
63/387
Najjar-Deb.. (PSM)
19%
0.81 [0.46-1.43]
22/2,661
27/2,661
Arbel 65+
74%
0.26 [0.10-0.73]
4/845
137/12,724
Arbel 40-64
-1182%
12.82 [3.41-48.2]
4/224
7/6,075
Suzuki (PSM)
-100%
2.00 [0.34-11.9]
2/230
3/690
PANORAMIC
Butler (RCT)
40%
0.60 [0.14-2.51]
3/12,529
5/12,525
Wong (PSM)
24%
0.76 [0.61-0.95]
Bajema (PSM)
18%
0.82 [0.52-1.29]
24/897
29.0/897
Inaba
58%
0.42 [0.02-10.1]
0/84
1/210
Goodwin
-110%
2.10 [0.19-22.9]
1/80
2/336
Tau2 = 0.20, I2 = 72.9%, p = 0.094
Early treatment
27%
0.73 [0.51-1.06]
81/20,458
284.0/39,122
27% lower risk
MOVe-IN
Arribas (DB RCT)
-282%
3.82 [0.50-29.1]
11/216
1/75
Improvement, RR [CI]
Treatment
Control
Wan
11%
0.89 [0.81-0.98]
704/6,153
2,541/17,283
Tau2 = 0.52, I2 = 49.4%, p = 0.71
Late treatment
-28%
1.28 [0.37-4.38]
715/6,369
2,542/17,358
28% higher risk
All studies
23%
0.77 [0.57-1.03]
796/26,827
2,826.0/56,480
23% lower risk
15 molnupiravir COVID-19 mortality results
c19 early .org Sep 2023
Tau2 = 0.14, I2 = 79.5%, p = 0.08
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wong (PSM)
58%
0.42 [0.17-1.01]
1,856 (n)
1,856 (n)
Improvement, RR [CI]
Treatment
Control
Flisiak
5%
0.95 [0.39-2.32]
7/203
14/387
Suzuki (PSM)
57%
0.43 [0.02-10.5]
0/230
1/690
Wong (PSM)
60%
0.40 [0.19-0.84]
Bajema (PSM)
17%
0.83 [0.17-4.12]
3/897
3.6/897
Tau2 = 0.00, I2 = 0.0%, p = 0.0083
Early treatment
46%
0.54 [0.34-0.85]
10/3,186
18.6/3,830
46% lower risk
All studies
46%
0.54 [0.34-0.85]
10/3,186
18.6/3,830
46% lower risk
5 molnupiravir COVID-19 mechanical ventilation results
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.0083
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Wong (PSM)
26%
0.74 [0.45-1.21]
Improvement, RR [CI]
Treatment
Control
Liu
-162%
2.62 [0.11-60.6]
1/26
0/16
Bajema (PSM)
1%
0.99 [0.41-2.37]
10/897
10.1/897
Tau2 = 0.00, I2 = 0.0%, p = 0.35
Early treatment
19%
0.81 [0.53-1.25]
11/923
10.1/913
19% lower risk
All studies
19%
0.81 [0.53-1.25]
11/923
10.1/913
19% lower risk
3 molnupiravir COVID-19 ICU results
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.35
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT)
-33%
1.33 [0.14-12.5]
hosp.
3/140
1/62
Improvement, RR [CI]
Treatment
Control
Hetero (RCT)
70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Tippabhotla (RCT)
46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM)
6%
0.94 [0.89-1.00]
hosp. time
1,856 (n)
1,856 (n)
Yip (PSW)
-17%
1.17 [0.99-1.39]
hosp.
Flisiak
-1%
1.01 [0.71-1.43]
hosp. time
203 (n)
387 (n)
AGILE CST-2
Khoo (DB RCT)
89%
0.11 [0.01-2.03]
hosp.
0/90
4/90
Arbel 65+
45%
0.55 [0.34-0.88]
hosp.
18/845
513/12,724
Arbel 40-64
-80%
1.80 [0.86-3.77]
hosp.
8/224
97/6,075
Brown
-101%
2.01 [0.43-9.38]
hosp.
8/442
2/222
PANORAMIC
Butler (RCT)
-7%
1.07 [0.81-1.41]
hosp.
103/12,529
96/12,525
Wong (PSM)
2%
0.98 [0.89-1.06]
hosp.
Liu
18%
0.82 [0.63-1.06]
hosp. time
26 (n)
16 (n)
Sinha (RCT)
65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Bajema (PSM)
-30%
1.30 [1.01-1.68]
hosp.
162/897
124.3/897
Inaba
-127%
2.27 [0.60-7.25]
hosp.
5/84
8/210
Goodwin
58%
0.42 [0.05-3.23]
hosp.
1/80
10/336
Tau2 = 0.02, I2 = 69.9%, p = 0.6
Early treatment
3%
0.97 [0.86-1.09]
331/19,005
917.3/36,990
3% lower risk
Wan
1%
0.99 [0.93-1.05]
hosp.
2,298/6,153
2,541/17,283
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.7
Late treatment
1%
0.99 [0.93-1.05]
2,298/6,153
2,541/17,283
1% lower risk
All studies
2%
0.98 [0.90-1.08]
2,629/25,158
3,458.3/54,273
2% lower risk
18 molnupiravir COVID-19 hospitalization results
c19 early .org Sep 2023
Tau2 = 0.01, I2 = 68.1%, p = 0.73
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT)
77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI]
Treatment
Control
Hetero (RCT)
70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
MOVe-OUT
Jayk Ber.. (DB RCT)
89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT)
46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM)
52%
0.48 [0.40-0.59]
death
1,856 (n)
1,856 (n)
Yip (PSW)
-12%
1.12 [0.68-1.82]
death/ICU
Flisiak
39%
0.61 [0.38-0.97]
death
20/203
63/387
AGILE CST-2
Khoo (DB RCT)
67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
Kneidinger
-15%
1.15 [0.56-2.37]
severe case
8/46
26/172
Najjar-Deb.. (PSM)
19%
0.81 [0.46-1.43]
death
22/2,661
27/2,661
Arbel 65+
74%
0.26 [0.10-0.73]
death
4/845
137/12,724
Arbel 40-64
-1182%
12.82 [3.41-48.2]
death
4/224
7/6,075
Suzuki (PSM)
-100%
2.00 [0.34-11.9]
death
2/230
3/690
Brown
-101%
2.01 [0.43-9.38]
hosp.
8/442
2/222
PANORAMIC
Butler (RCT)
40%
0.60 [0.14-2.51]
death
3/12,529
5/12,525
Wong (PSM)
24%
0.76 [0.61-0.95]
death
Liu
-162%
2.62 [0.11-60.6]
ICU
1/26
0/16
Sinha (RCT)
65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Zheng
-100%
2.00 [1.23-3.23]
death/hosp.
61/2,689
34/3,331
OT1
Bajema (PSM)
18%
0.82 [0.52-1.29]
death
24/897
29.0/897
Inaba
58%
0.42 [0.02-10.1]
death
0/84
1/210
Zheng (PSW)
-285%
3.85 [1.54-10.0]
death/hosp.
11/802
33/4,836
OT1
Evans
51%
0.49 [0.29-0.83]
death/hosp.
359 (n)
4,973 (n)
Goodwin
-110%
2.10 [0.19-22.9]
death
1/80
2/336
Tazare
-9%
1.09 [0.93-1.27]
death/hosp.
Butt
-9%
1.09 [0.73-1.63]
death/hosp.
48/1,459
44/1,459
Tau2 = 0.25, I2 = 81.6%, p = 0.28
Early treatment
14%
0.86 [0.67-1.12]
241/27,960
486.0/55,811
14% lower risk
MOVe-IN
Arribas (DB RCT)
-282%
3.82 [0.50-29.1]
death
11/216
1/75
Improvement, RR [CI]
Treatment
Control
Wan
11%
0.89 [0.81-0.98]
death
704/6,153
2,541/17,283
Tau2 = 0.52, I2 = 49.4%, p = 0.71
Late treatment
-28%
1.28 [0.37-4.38]
715/6,369
2,542/17,358
28% higher risk
All studies
12%
0.88 [0.71-1.08]
956/34,329
3,028.0/73,169
12% lower risk
28 molnupiravir COVID-19 serious outcomes
c19 early .org Sep 2023
Tau2 = 0.14, I2 = 80.5%, p = 0.21
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hetero (RCT)
33%
0.67 [0.54-0.82]
recov. time
371 (n)
370 (n)
Improvement, RR [CI]
Treatment
Control
Khoo (RCT)
-33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
MOVe-OUT
Jayk Ber.. (DB RCT)
15%
0.85 [0.75-0.98]
recovery
709 (n)
699 (n)
Zou (RCT)
29%
0.71 [0.28-1.85]
recov. time
77 (n)
31 (n)
AGILE CST-2
Khoo (DB RCT)
-12%
1.12 [0.71-1.79]
no recov.
27/90
24/90
PANORAMIC
Butler (RCT)
22%
0.78 [0.75-0.81]
no recov.
3,856/12,403
4,838/12,140
Tau2 = 0.00, I2 = 36.4%, p < 0.0001
Early treatment
20%
0.80 [0.72-0.88]
3,891/13,662
4,865/13,336
20% lower risk
033864 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING1
Improvement, RR [CI]
Treatment
Control
035424 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING1
MOVe-IN
Arribas (DB RCT)
1%
0.99 [0.68-1.45]
no recov.
72 (n)
75 (n)
Tau2 = 0.00, I2 = 0.0%, p = 0.97
Late treatment
1%
0.99 [0.74-1.34]
0/72
0/75
1% lower risk
All studies
19%
0.81 [0.74-0.88]
3,891/13,734
4,865/13,411
19% lower risk
9 molnupiravir COVID-19 recovery results
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 22.1%, p < 0.0001
1 FUTILITY: terminated for futility, results pending
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
MOVe-AHEAD
Alpizar (DB RCT)
24%
0.76 [0.57-1.01]
symp. case
78/763
103/764
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.049
Prophylaxis
24%
0.76 [0.57-1.01]
78/763
103/764
24% lower risk
All studies
24%
0.76 [0.57-1.01]
78/763
103/764
24% lower risk
1 molnupiravir COVID-19 case result
c19 early .org Sep 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.049
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT)
49%
0.51 [0.22-1.18]
viral+
10/118
9/54
Improvement, RR [CI]
Treatment
Control
Optimus (RCT)
58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Tippabhotla (RCT)
59%
0.41 [0.29-0.57]
viral+
42/610
103/610
Wong (PSM)
28%
0.72 [0.61-0.87]
viral+
1,856 (n)
1,856 (n)
Zou (RCT)
10%
0.90 [0.83-0.97]
viral time
76 (n)
31 (n)
AGILE CST-2
Khoo (DB RCT)
23%
0.77 [0.58-1.09]
viral+
90 (n)
90 (n)
PANORAMIC
Butler (RCT)
-95%
1.95 [1.15-3.31]
viral load
21 (n)
11 (n)
Liu
21%
0.79 [0.59-1.05]
viral time
26 (n)
16 (n)
Sinha (RCT)
48%
0.52 [0.42-0.63]
viral load
608 (n)
610 (n)
Tau2 = 0.10, I2 = 88.8%, p = 0.0017
Early treatment
32%
0.68 [0.54-0.87]
90/3,580
205/3,458
32% lower risk
MOVe-IN
Arribas (DB RCT)
12%
0.88 [0.62-1.25]
viral+
26/52
34/60
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.49
Late treatment
12%
0.88 [0.62-1.25]
26/52
34/60
12% lower risk
All studies
30%
0.70 [0.56-0.87]
116/3,632
239/3,518
30% lower risk
10 molnupiravir COVID-19 viral clearance results
c19 early .org Sep 2023
Tau2 = 0.10, I2 = 87.5%, p = 0.0015
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT)
77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI]
Treatment
Control
Hetero (RCT)
70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Optimus (RCT)
58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Khoo (RCT)
-33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
MOVe-OUT
Jayk Ber.. (DB RCT)
89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT)
46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Zou (RCT)
29%
0.71 [0.28-1.85]
recov. time
77 (n)
31 (n)
AGILE CST-2
Khoo (DB RCT)
67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
PANORAMIC
Butler (RCT)
40%
0.60 [0.14-2.51]
death
3/12,529
5/12,525
Sinha (RCT)
65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Tau2 = 0.03, I2 = 13.1%, p < 0.0001
Early treatment
54%
0.46 [0.35-0.63]
73/15,321
174/15,183
54% lower risk
033864 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING1
Improvement, RR [CI]
Treatment
Control
035424 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING1
MOVe-IN
Arribas (DB RCT)
-282%
3.82 [0.50-29.1]
death
11/216
1/75
Tau2 = 0.00, I2 = 0.0%, p = 0.77
Late treatment
-8%
1.08 [0.67-1.73]
11/216
1/75
8% higher risk
MOVe-AHEAD
Alpizar (DB RCT)
24%
0.76 [0.57-1.01]
symp. case
78/763
103/764
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.049
Prophylaxis
24%
0.76 [0.57-1.01]
78/763
103/764
24% lower risk
All studies
38%
0.62 [0.46-0.84]
162/16,300
278/16,022
38% lower risk
14 molnupiravir COVID-19 Randomized Controlled Trials
c19 early .org Sep 2023
Tau2 = 0.12, I2 = 49.8%, p = 0.0021
Effect extraction pre-specified
1 FUTILITY: terminated for futility, results pending
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT)
77%
0.23 [0.01-5.69]
0/140
1/62
Improvement, RR [CI]
Treatment
Control
MOVe-OUT
Jayk Ber.. (DB RCT)
89%
0.11 [0.01-0.86]
1/709
9/699
PANORAMIC
Butler (RCT)
40%
0.60 [0.14-2.51]
3/12,529
5/12,525
Tau2 = 0.00, I2 = 0.0%, p = 0.048
Early treatment
67%
0.33 [0.11-0.99]
4/13,378
15/13,286
67% lower risk
MOVe-IN
Arribas (DB RCT)
-282%
3.82 [0.50-29.1]
11/216
1/75
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.2
Late treatment
-282%
3.82 [0.50-29.1]
11/216
1/75
282% higher risk
All studies
45%
0.55 [0.13-2.38]
15/13,594
16/13,361
45% lower risk
4 molnupiravir COVID-19 RCT mortality results
c19 early .org Sep 2023
Tau2 = 1.13, I2 = 51.1%, p = 0.43
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hetero (RCT)
70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Improvement, RR [CI]
Treatment
Control
Khoo (RCT)
-33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
MOVe-OUT
Jayk Ber.. (DB RCT)
89%
0.11 [0.01-0.86]
death
1/709
9/699
Tippabhotla (RCT)
46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Wong (PSM)
52%
0.48 [0.40-0.59]
death
1,856 (n)
1,856 (n)
Yip (PSW)
-12%
1.12 [0.68-1.82]
death/ICU
Zou (RCT)
29%
0.71 [0.28-1.85]
recov. time
77 (n)
31 (n)
Flisiak
39%
0.61 [0.38-0.97]
death
20/203
63/387
AGILE CST-2
Khoo (DB RCT)
67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
Kneidinger
-15%
1.15 [0.56-2.37]
severe case
8/46
26/172
Najjar-Deb.. (PSM)
19%
0.81 [0.46-1.43]
death
22/2,661
27/2,661
Suzuki (PSM)
-100%
2.00 [0.34-11.9]
death
2/230
3/690
Brown
-101%
2.01 [0.43-9.38]
hosp.
8/442
2/222
PANORAMIC
Butler (RCT)
40%
0.60 [0.14-2.51]
death
3/12,529
5/12,525
Wong (PSM)
24%
0.76 [0.61-0.95]
death
Liu
-162%
2.62 [0.11-60.6]
ICU
1/26
0/16
Sinha (RCT)
65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Zheng
-100%
2.00 [1.23-3.23]
death/hosp.
61/2,689
34/3,331
OT1
Evans
51%
0.49 [0.29-0.83]
death/hosp.
359 (n)
4,973 (n)
Goodwin
-110%
2.10 [0.19-22.9]
death
1/80
2/336
Butt
-9%
1.09 [0.73-1.63]
death/hosp.
48/1,459
44/1,459
Tau2 = 0.18, I2 = 73.0%, p = 0.048
Early treatment
23%
0.77 [0.60-1.00]
206/25,057
281/31,044
23% lower risk
MOVe-IN
Arribas (DB RCT)
-282%
3.82 [0.50-29.1]
death
11/216
1/75
Improvement, RR [CI]
Treatment
Control
Wan
11%
0.89 [0.81-0.98]
death
704/6,153
2,541/17,283
Tau2 = 0.52, I2 = 49.4%, p = 0.71
Late treatment
-28%
1.28 [0.37-4.38]
715/6,369
2,542/17,358
28% higher risk
MOVe-AHEAD
Alpizar (DB RCT)
24%
0.76 [0.57-1.01]
symp. case
78/763
103/764
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.049
Prophylaxis
24%
0.76 [0.57-1.01]
78/763
103/764
24% lower risk
All studies
21%
0.79 [0.65-0.96]
999/32,189
2,926/49,166
21% lower risk
24 molnupiravir COVID-19 peer reviewed studies
c19 early .org Sep 2023
Tau2 = 0.10, I2 = 73.2%, p = 0.018
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment
Favors molnupiravir
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Fischer (RCT)
77%
0.23 [0.01-5.69]
death
0/140
1/62
Improvement, RR [CI]
Treatment
Control
Fischer (RCT)
65%
0.35 [0.01-8.33]
death
0/55
1/62
Fischer (RCT)
67%
0.33 [0.01-8.03]
death
0/62
1/62
Fischer (RCT)
58%
0.42 [0.02-10.0]
death
0/23
1/62
Fischer (RCT)
-33%
1.33 [0.14-12.5]
hosp.
3/140
1/62
Fischer (RCT)
-13%
1.13 [0.07-17.6]
hosp.
1/55
1/62
Fischer (RCT)
-100%
2.00 [0.19-21.5]
hosp.
2/62
1/62
Fischer (RCT)
58%
0.42 [0.02-10.0]
hosp.
0/23
1/62
Fischer (RCT)
49%
0.51 [0.22-1.18]
viral+
10/118
9/54
Fischer (RCT)
89%
0.11 [0.01-0.86]
viral+
1/53
9/54
Fischer (RCT)
30%
0.70 [0.25-1.93]
viral+
5/43
9/54
Fischer (RCT)
-9%
1.09 [0.37-3.18]
viral+
4/22
9/54
Fischer (RCT)
92%
0.08 [0.01-0.62]
viral+
1/117
6/54
Fischer (RCT)
92%
0.08 [0.01-0.75]
viral+
0/53
6/54
Fischer (RCT)
91%
0.09 [0.01-0.83]
viral+
0/42
6/54
Fischer (RCT)
59%
0.41 [0.05-3.20]
viral+
1/22
6/54
Fischer (RCT)
30%
0.70 [0.37-1.36]
viral+
19/137
12/61
Fischer (RCT)
62%
0.38 [0.13-1.12]
viral+
4/53
12/61
Fischer (RCT)
-8%
1.08 [0.54-2.18]
viral+
13/61
12/61
Fischer (RCT)
56%
0.44 [0.11-1.83]
viral+
2/23
12/61
Hetero (RCT)
70%
0.30 [0.13-0.70]
hosp.
7/371
23/370
Hetero (RCT)
33%
0.67 [0.54-0.82]
recov. time
371 (n)
370 (n)
Optimus (RCT)
58%
0.42 [0.31-0.58]
viral+
38/175
93/180
Khoo (RCT)
-33%
1.33 [0.55-3.26]
no recov.
8/12
3/6
Khoo (RCT)
-100%
2.00 [0.28-14.2]
no recov.
4/12
1/6
Khoo (RCT)
-100%
2.00 [0.90-4.43]
no recov.
4/4
3/6
Khoo (RCT)
0%
1.00 [0.28-3.54]
no recov.
2/4
3/6
Khoo (RCT)
0%
1.00 [0.28-3.54]
no recov.
2/4
3/6
Khoo (RCT)
-50%
1.50 [0.13-17.7]
no recov.
1/4
1/6
Khoo (RCT)
-200%
3.00 [0.39-23.1]
no recov.
2/4
1/6
Khoo (RCT)
-50%
1.50 [0.13-17.7]
no recov.
1/4
1/6
MOVe-OUT
Jayk Ber.. (DB RCT)
89%
0.11 [0.01-0.86]
death
1/709
9/699
MOVe-OUT
Jayk Ber.. (DB RCT)
30%
0.70 [0.48-1.00]
death/hosp.
48/709
68/699
MOVe-OUT
Jayk Ber.. (DB RCT)
94%
0.06 [0.00-0.97]
death/hosp.
0/37
9/47
MOVe-OUT
Jayk Ber.. (DB RCT)
50%
0.50 [0.20-1.26]
death/hosp.
6/75
13/82
MOVe-OUT
Jayk Ber.. (DB RCT)
24%
0.76 [0.42-1.38]
death/hosp.
18/237
22/221
MOVe-OUT
Jayk Ber.. (DB RCT)
42%
0.58 [0.20-1.68]
death/hosp.
5/47
7/38
MOVe-OUT
Jayk Ber.. (DB RCT)
15%
0.85 [0.75-0.98]
recovery
709 (n)
699 (n)
MOVe-OUT
Jayk Ber.. (DB RCT)
19%
0.81 [0.71-0.92]
recovery
709 (n)
699 (n)
MOVe-OUT
Jayk Ber.. (DB RCT)
15%
0.85 [0.75-0.97]
recovery
709 (n)
699 (n)
MOVe-OUT
Jayk Ber.. (DB RCT)
14%
0.86 [0.76-0.97]
recovery
709 (n)
699 (n)
Tippabhotla (RCT)
46%
0.54 [0.22-1.34]
hosp.
7/610
13/610
Tippabhotla (RCT)
46%
0.54 [0.41-0.71]
no improv.
67/610
125/610
Tippabhotla (RCT)
52%
0.48 [0.42-0.54]
no improv.
199/610
417/610
Tippabhotla (RCT)
25%
0.75 [0.71-0.79]
no improv.
433/610
576/610
Tippabhotla (RCT)
59%
0.41 [0.29-0.57]
viral+
42/610
103/610
Tippabhotla (RCT)
81%
0.19 [0.15-0.24]
viral+
62/610
327/610
Tippabhotla (RCT)
78%
0.22 [0.19-0.27]
viral+
113/610
505/610
Wong (PSM)
52%
0.48 [0.40-0.59]
death
1,856 (n)
1,856 (n)
Wong (PSM)
58%
0.42 [0.17-1.01]
ventilation
1,856 (n)
1,856 (n)
Wong (PSM)
40%
0.60 [0.52-0.69]
progression
1,856 (n)
1,856 (n)
Wong (PSM)
6%
0.94 [0.89-1.00]
hosp. time
1,856 (n)
1,856 (n)
Wong (PSM)
28%
0.72 [0.61-0.87]
viral+
1,856 (n)
1,856 (n)
Yip (PSW)
-12%
1.12 [0.68-1.82]
death/ICU
Yip (PSW)
-17%
1.17 [0.99-1.39]
hosp.
Zou (RCT)
29%
0.71 [0.28-1.85]
recov. time
77 (n)
31 (n)
Zou (RCT)
10%
0.90 [0.83-0.97]
viral time
76 (n)
31 (n)
Zou (RCT)
51%
0.49 [0.28-0.84]
viral+
18/76
15/31
Zou (RCT)
37%
0.63 [0.51-0.78]
viral+
45/76
29/31
Zou (RCT)
18%
0.82 [0.73-0.92]
viral+
62/76
31/31
Flisiak
39%
0.61 [0.38-0.97]
death
20/203
63/387
Flisiak
5%
0.95 [0.39-2.32]
ventilation
7/203
14/387
Flisiak
-1%
1.01 [0.71-1.43]
hosp. time
203 (n)
387 (n)
AGILE CST-2
Khoo (DB RCT)
67%
0.33 [0.01-8.08]
oxygen
0/90
1/90
AGILE CST-2
Khoo (DB RCT)
89%
0.11 [0.01-2.03]
hosp.
0/90
4/90
AGILE CST-2
Khoo (DB RCT)
-12%
1.12 [0.71-1.79]
no recov.
27/90
24/90
AGILE CST-2
Khoo (DB RCT)
23%
0.77 [0.58-1.09]
viral+
90 (n)
90 (n)
Kneidinger
-15%
1.15 [0.56-2.37]
severe case
8/46
26/172
Najjar-Deb.. (PSM)
19%
0.81 [0.46-1.43]
death
22/2,661
27/2,661
Najjar-Deb.. (PSM)
17%
0.83 [0.57-1.21]
progression
50/2,661
60/2,661
Najjar-Deb.. (PSM)
25%
0.75 [0.51-1.12]
severe case
43/2,661
57/2,661
Arbel 65+
74%
0.26 [0.10-0.73]
death
4/845
137/12,724
Arbel 65+
-1182%
12.82 [3.41-48.2]
death
4/224
7/6,075
Arbel 65+
45%
0.55 [0.34-0.88]
hosp.
18/845
513/12,724
Arbel 65+
-80%
1.80 [0.86-3.77]
hosp.
8/224
97/6,075
Arbel 40-64
-1182%
12.82 [3.41-48.2]
death
4/224
7/6,075
Arbel 40-64
-80%
1.80 [0.86-3.77]
hosp.
8/224
97/6,075
Suzuki (PSM)
-100%
2.00 [0.34-11.9]
death
2/230
3/690
Suzuki (PSM)
57%
0.43 [0.02-10.5]
ventilation
0/230
1/690
Suzuki (PSM)
53%
0.47 [0.22-0.98]
progression
9/230
58/690
Brown
-101%
2.01 [0.43-9.38]
hosp.
8/442
2/222
PANORAMIC
Butler (RCT)
40%
0.60 [0.14-2.51]
death
3/12,529
5/12,525
PANORAMIC
Butler (RCT)
-6%
1.06 [0.81-1.41]
death/hosp.
105/12,529
98/12,525
PANORAMIC
Butler (RCT)
-7%
1.07 [0.81-1.41]
hosp.
103/12,529
96/12,525
PANORAMIC
Butler (RCT)
2%
0.98 [0.94-1.01]
transmission
3,887/10,803
3,873/10,548
PANORAMIC
Butler (RCT)
22%
0.78 [0.75-0.81]
no recov.
3,856/12,403
4,838/12,140
PANORAMIC
Butler (RCT)
19%
0.81 [0.78-0.83]
recov. time
12,403 (n)
12,140 (n)
PANORAMIC
Butler (RCT)
30%
0.70 [0.67-0.73]
no recov.
2,675/12,403
3,766/12,140
PANORAMIC
Butler (RCT)
26%
0.74 [0.71-0.76]
recov. time
12,403 (n)
12,140 (n)
PANORAMIC
Butler (RCT)
-95%
1.95 [1.15-3.31]
viral load
21 (n)
11 (n)
PANORAMIC
Butler (RCT)
92%
0.08 [0.05-0.14]
viral load
33 (n)
26 (n)
Wong (PSM)
24%
0.76 [0.61-0.95]
death
Wong (PSM)
60%
0.40 [0.19-0.84]
ventilation
Wong (PSM)
26%
0.74 [0.45-1.21]
ICU
Wong (PSM)
2%
0.98 [0.89-1.06]
hosp.
Liu
-162%
2.62 [0.11-60.6]
ICU
1/26
0/16
Liu
8%
0.92 [0.17-4.94]
progression
3/26
2/16
Liu
18%
0.82 [0.63-1.06]
hosp. time
26 (n)
16 (n)
Liu
21%
0.79 [0.59-1.05]
viral time
26 (n)
16 (n)
Liu
-23%
1.23 [0.12-12.5]
viral+
2/26
1/16
Liu
28%
0.72 [0.29-1.76]
viral+
7/26
6/16
Liu
38%
0.62 [0.41-0.92]
viral+
14/26
14/16
Liu
18%
0.82 [0.64-1.05]
viral+
20/26
15/16
Liu
12%
0.88 [0.75-1.05]
viral+
23/26
16/16
Sinha (RCT)
65%
0.35 [0.16-0.73]
hosp.
9/608
26/610
Sinha (RCT)
53%
0.47 [0.26-0.85]
no improv.
16/608
34/610
Sinha (RCT)
48%
0.52 [0.42-0.63]
viral load
608 (n)
610 (n)
Zheng
-100%
2.00 [1.23-3.23]
death/hosp.
61/2,689
34/3,331
OT1
Zheng
-85%
1.85 [1.14-3.03]
death/hosp.
55/2,689
32/3,331
OT1
Bajema (PSM)
18%
0.82 [0.52-1.29]
death
24/897
29.0/897
Bajema (PSM)
49%
0.51 [0.20-1.27]
death
7/897
13.8/897
Bajema (PSM)
17%
0.83 [0.17-4.12]
ventilation
3/897
3.6/897
Bajema (PSM)
1%
0.99 [0.41-2.37]
ICU
10/897
10.1/897
Bajema (PSM)
-30%
1.30 [1.01-1.68]
hosp.
162/897
124.3/897
Bajema (PSM)
9%
0.91 [0.59-1.41]
hosp.
37/897
40.5/897
Inaba
58%
0.42 [0.02-10.1]
death
0/84
1/210
Inaba
-127%
2.27 [0.60-7.25]
death/hosp.
5/84
8/210
Inaba
-127%
2.27 [0.60-7.25]
hosp.
5/84
8/210
Zheng (PSW)
-285%
3.85 [1.54-10.0]
death/hosp.
11/802
33/4,836
OT1
Evans
51%
0.49 [0.29-0.83]
death/hosp.
359 (n)
4,973 (n)
Goodwin
-110%
2.10 [0.19-22.9]
death
1/80
2/336
Goodwin
58%
0.42 [0.05-3.23]
hosp.
1/80
10/336
Goodwin
53%
0.47 [0.11-1.97]
hosp.
2/80
18/336
Tazare
-9%
1.09 [0.93-1.27]
death/hosp.
Butt
-9%
1.09 [0.73-1.63]
death/hosp.
48/1,459
44/1,459
033864 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING2
035424 (RCT)
0%
1.00 [0.50-2.00]
improv.
n/a
n/a
FUTILITY, PENDING2
MOVe-IN
Arribas (DB RCT)
-282%
3.82 [0.50-29.1]
death
11/216
1/75
MOVe-IN
Arribas (DB RCT)
-217%
3.17 [0.34-29.8]
death
3/71
1/75
MOVe-IN
Arribas (DB RCT)
-317%
4.17 [0.48-36.4]
death
4/72
1/75
MOVe-IN
Arribas (DB RCT)
-311%
4.11 [0.47-35.9]
death
4/73
1/75
MOVe-IN
Arribas (DB RCT)
1%
0.99 [0.68-1.45]
no recov.
72 (n)
75 (n)
MOVe-IN
Arribas (DB RCT)
12%
0.88 [0.61-1.28]
no recov.
73 (n)
75 (n)
MOVe-IN
Arribas (DB RCT)
-1%
1.01 [0.69-1.47]
no recov.
73 (n)
75 (n)
MOVe-IN
Arribas (DB RCT)
12%
0.88 [0.62-1.25]
viral+
26/52
34/60
MOVe-IN
Arribas (DB RCT)
-2%
1.02 [0.74-1.41]
viral+
29/50
34/60
MOVe-IN
Arribas (DB RCT)
21%
0.79 [0.56-1.13]
viral+
27/60
34/60
MOVe-IN
Arribas (DB RCT)
8%
0.92 [0.41-2.08]
viral+
9/53
10/54
MOVe-IN
Arribas (DB RCT)
-48%
1.48 [0.72-3.03]
viral+
14/51
10/54
MOVe-IN
Arribas (DB RCT)
21%
0.79 [0.34-1.84]
viral+
8/55
10/54
Wan
11%
0.89 [0.81-0.98]
death
704/6,153
2,541/17,283
Wan
1%
0.99 [0.93-1.05]
hosp.
2,298/6,153
2,541/17,283
Wan
-4%
1.04 [0.98-1.10]
progression
2,300/6,153
2,541/17,283
MOVe-AHEAD
Alpizar (DB RCT)
24%
0.76 [0.57-1.01]
symp. case
78/763
103/764
Molnupiravir COVID-19 outcomes
c19 early .org Sep 2023
1 OT: comparison with other treatment 2 FUTILITY: terminated for futility, results pending
Favors molnupiravir
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit